{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:33:37Z","timestamp":1791959617739,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Research Foundation for Microbial Diseases of Osaka University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-3719-7","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T13:03:32Z","timestamp":1548680612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study"],"prefix":"10.1186","volume":"19","author":[{"given":"Satoko","family":"Ohfuji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kumashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kayano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"3719_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1086\/653605","volume":"51","author":"MN Oxman","year":"2010","unstructured":"Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51:197\u2013213. \n                    https:\/\/doi.org\/10.1086\/653605\n                    \n                  .","journal-title":"Clin Infect Dis"},{"key":"3719_CR2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1086\/379048","volume":"188","author":"MJ Levin","year":"2003","unstructured":"Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003;188:1336\u201344.","journal-title":"J Infect Dis"},{"key":"3719_CR3","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/jmv.21599.","volume":"81","author":"N Toyama","year":"2009","unstructured":"Toyama N, Shiraki K. Society of the Miyazaki Prefecture Dermatologists. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol. 2009;81:2053\u20138. \n                    https:\/\/doi.org\/10.1002\/jmv.21599.","journal-title":"J Med Virol"},{"key":"3719_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/1346-8138.13639","volume":"44","author":"K Sato","year":"2017","unstructured":"Sato K, Adachi K, Nakamura H, Asano K, Watanabe A, Adachi R, et al. Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: results from an observational, prospective, physician practice-based cohort study. J Dermatol. 2017;44:414\u201322. \n                    https:\/\/doi.org\/10.1111\/1346-8138.13639\n                    \n                  .","journal-title":"J Dermatol"},{"key":"3719_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2188\/jea.JE20140210","volume":"25","author":"Y Takao","year":"2015","unstructured":"Takao Y, Miyazaki Y, Okeda M, Onishi F, Yano S, Gomi Y, et al. Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study. J Epidemiol. 2015;25:617\u201325. \n                    https:\/\/doi.org\/10.2188\/jea.JE20140210\n                    \n                  .","journal-title":"J Epidemiol"},{"key":"3719_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s15010-011-0162-0","volume":"39","author":"A Hata","year":"2011","unstructured":"Hata A, Kuniyoshi M, Ohkusa Y. Risk of herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39:537\u201344. \n                    https:\/\/doi.org\/10.1007\/s15010-011-0162-0\n                    \n                  .","journal-title":"Infection"},{"key":"3719_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s13300-018-0394-4","volume":"9","author":"M Papagianni","year":"2018","unstructured":"Papagianni M, Metallidis S, Tziomalos K. Herpes zoster and diabetes mellitus: a review. Diabetes Ther. 2018;9:545\u201350. \n                    https:\/\/doi.org\/10.1007\/s13300-018-0394-4\n                    \n                  .","journal-title":"Diabetes Ther"},{"key":"3719_CR8","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271\u201384.","journal-title":"N Engl J Med"},{"key":"3719_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.11150\/kansenshogakuzasshi.85.161","volume":"85","author":"H Kamiya","year":"2011","unstructured":"Kamiya H, Asano Y, Ozaki T, Baba K, Kumagai T, Nagai T, et al. Varicella vaccine potency and stability during transport and delivery. Kansenshogaku Zasshi. 2011;85:161\u20135 (In Japanese).","journal-title":"Kansenshogaku Zasshi"},{"key":"3719_CR10","first-page":"963","volume":"30","author":"S Okada","year":"2014","unstructured":"Okada S, Kataoka C, Akechi M. An examination of the immunogenicity and safety of BK1303 (freeze-dried live attenuated varicella vaccine) in healthy adults aged 50 years or older: a phase III, single-center, open-label, uncontrolled trial. J Clin Ther Med. 2014;30:963\u201374 (In Japanese).","journal-title":"J Clin Ther Med"},{"key":"3719_CR11","doi-asserted-by":"publisher","unstructured":"Benson CA, Andersen JW, Macatangay BJC, Mailliard RB, Rinaldo CR Jr, Read S, et al. Safety and immunogenicity of zoster vaccine live in HIV-infected adults with CD4+ cell counts above 200 cells\/ml virologically supperessed on antiretroviral therapy. Clin Infect Dis. 2018 (In Press. \n                    https:\/\/doi.org\/10.1093\/cid\/ciy242\n                    \n                  .","DOI":"10.1093\/cid\/ciy242"},{"key":"3719_CR12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/dme.13038","volume":"33","author":"A Hata","year":"2016","unstructured":"Hata A, Inoue F, Hamamoto Y, Yamasaki M, Fujikawa J, Kawahara H, et al. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2016;33:1094\u2013101. \n                    https:\/\/doi.org\/10.1111\/dme.13038\n                    \n                  .","journal-title":"Diabet Med"},{"key":"3719_CR13","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1016\/j.vaccine.2015.04.090","volume":"33","author":"AF Russell","year":"2015","unstructured":"Russell AF, Parrino J, Fisher CL Jr, Spieler W, Stek JE, Coll KE, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic\/maintenance corticosteroids. Vaccine. 2015;33:3129\u201334. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.090\n                    \n                  .","journal-title":"Vaccine"},{"key":"3719_CR14","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54:922\u20138. \n                    https:\/\/doi.org\/10.1093\/cid\/cir970\n                    \n                  .","journal-title":"Clin Infect Dis"},{"key":"3719_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004.","volume":"152","author":"MS Simberkoff","year":"2010","unstructured":"Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, et al. Shingles prevention study group. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010;152:545\u201354. \n                    https:\/\/doi.org\/10.7326\/0003-4819-152-9-201005040-00004.","journal-title":"Ann Intern Med"},{"key":"3719_CR16","doi-asserted-by":"publisher","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","volume":"35","author":"ED Willis","year":"2017","unstructured":"Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, et al. Herpes zoster vaccine live: a 10 year review of post-marketing safety experience. Vaccine. 2017;35:7231\u20139. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.013\n                    \n                  .","journal-title":"Vaccine"},{"key":"3719_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/infdis\/jit182.","volume":"208","author":"VA Morrison","year":"2013","unstructured":"Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, et al. Shingles prevention study group. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013;208:559\u201363. \n                    https:\/\/doi.org\/10.1093\/infdis\/jit182.","journal-title":"J Infect Dis"},{"key":"3719_CR18","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1086\/644646","volume":"200","author":"S Okamoto","year":"2009","unstructured":"Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis. 2009;200:1606\u201310. \n                    https:\/\/doi.org\/10.1086\/644646\n                    \n                  .","journal-title":"J Infect Dis"},{"key":"3719_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jinf.2013.04.010","volume":"67","author":"A Hata","year":"2013","unstructured":"Hata A, Inoue F, Yamasaki M, Fujikawa J, Kawasaki Y, Hamamoto Y, et al. Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus. J Inf Secur. 2013;67:215\u20139. \n                    https:\/\/doi.org\/10.1016\/j.jinf.2013.04.010\n                    \n                  .","journal-title":"J Inf Secur"},{"key":"3719_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3899\/jrheum.170936","volume":"45","author":"JH Koh","year":"2018","unstructured":"Koh JH, Lee J, Kim SH, Kwok SK, Ju JH, Park SH. Safety, and humoral and cell-mediated immune responses to herpes zoster vaccine in patients with rheumatoid arthritis. J Rheumatol. 2018;45:465\u20139. \n                    https:\/\/doi.org\/10.3899\/jrheum.170936\n                    \n                  .","journal-title":"J Rheumatol"},{"key":"3719_CR21","first-page":"43","volume":"308","author":"J Zhang","year":"2012","unstructured":"Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43\u20139.","journal-title":"JAMA"},{"key":"3719_CR22","doi-asserted-by":"publisher","first-page":"e1001420","DOI":"10.1371\/journal.pmed.1001420","volume":"10","author":"SM Langan","year":"2013","unstructured":"Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10:e1001420. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.1001420\n                    \n                  .","journal-title":"PLoS Med"},{"key":"3719_CR23","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1093\/ndt\/gfv432","volume":"31","author":"SM Langan","year":"2016","unstructured":"Langan SM, Thomas SL, Smeeth L, Margolis DJ, Nitsch D. Zoster vaccination is associated with a reduction of zoster in elderly patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31:2095\u20138.","journal-title":"Nephrol Dial Transplant"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-3719-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:07:44Z","timestamp":1580170064000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-3719-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3719"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-3719-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocols were approved by the Clinical Study Review Board of SOUSEIKAI (No. 1668CP) and BIKEN Ethical and COI Review Board (No.16\u201303), and was performed in accordance with the Declaration of Helsinki. All participants received an explanation of the study from their physician and provided written, informed consent prior to participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EK and NO are members of the Research Foundation for Microbial Diseases of Osaka University (funding company). Other authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"95"}}